Moncef Slaoui

Moncef Slaoui currently works at Altesa BioSciences, Inc., as Chairman, Arcturus Therapeutics Holdings, Inc., as Chairman from 2025, Biotechnology Innovation Organization, as Director, Zephyr AI, Inc., as Director, Monopteros Therapeutics, Inc., as Director, Vaxcyte, Inc., as Independent Director from 2026, and Medicxi Ventures (Jersey) Ltd., as Venture Partner from 2017.
Dr. Slaoui also formerly worked at Genelabs Technologies, Inc., as Director, Chairman-Research & Development, GSK Plc, as Director, Chairman-Global Research & Development from 2013 to 2014, Vaxcyte, Inc., as Chairman from 2018 to 2021, Galvani Bioelectronics Ltd., as Chairman from 2016 to 2021, International AIDS Vaccine Initiative, Inc., as Director, Lonza Group AG, as Independent Director in 2020, Agency for Science, Technology & Research, as Director, Pharmaceutical Research & Manufacturers of America, as Director, Longwood Fund Management LLC, as Director & Strategic Advisor, ModernaTX, Inc., as Director, PhRMA Foundation, as Director from 2008 to 2016, Intellia Therapeutics, Inc., as Director in 2017, Artizan Biosciences, Inc., as Director, Moderna, Inc., as Independent Non-Executive Director from 2017 to 2020, the University of Mons Hainaut, as Immunology Professor, and Université de Mons, as Professor.
Dr. Slaoui received his graduate degree from Tufts University, doctorate degree from Université Libre de Bruxelles, Masters Business Admin degree in 1998 from International Institute for Management Development, and graduate degree from Harvard Medical School.